ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
December 24, 2018Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for ....... -
Jazz Pharmaceuticals Submits MAA to European Medicines Agency for Solriamfetol
November 10, 2018Jazz Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, as a treatment to improve wakefulness and reduce ex
Pharma Sources Insight January 2025
